Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
ChiCTR2000040099Phase 2Not yet recruiting
- Sponsor
- Air Force Specialty Medical Center
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Air Force Specialty Medical Center. Primary endpoint: Safety. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000040099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040099.